Core Insights - Ascentage Pharma Group International has announced that results from two clinical studies of its drug, lisaftoclax (APG-2575), will be presented at the 67th American Society of Hematology (ASH) Annual Meeting, marking the fourth consecutive year for such presentations [1][2][4] Clinical Study Results - Lisaftoclax is an orally available Bcl-2 inhibitor showing efficacy in hematologic malignancies and solid tumors, currently approved in China for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received prior systemic therapy [2][18] - At ASH 2025, an oral report will present results from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed/refractory CLL/SLL, while a poster will feature data on its combination with azacitidine in newly diagnosed or prior venetoclax-exposed myeloid malignancies [2][11] Efficacy and Safety Data - In the Phase II study, among 72 evaluable patients with R/R CLL/SLL, the objective response rate (ORR) was 62.5%, with a median progression-free survival (mPFS) of 23.89 months [8][10] - The treatment demonstrated a manageable safety profile, with frequent grade ≥3 treatment-related adverse events primarily being hematologic toxicities, and no treatment-related deaths reported [9][10] Additional Presentations - The ASH Annual Meeting will also feature presentations on other investigational drug candidates from Ascentage Pharma, including olverembatinib and APG-5918, showcasing the company's robust capabilities in clinical development [4][5][19]

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), the allocation of 315,639 new shares in a retail offering via the PrimaryBid platform (the "PrimaryBid Offering"), and a potential subsequent repair offering of up to 800,000 new shares at the same subscription price as in the Private Placement and the PrimaryBid Offering (the "Subsequent ...

Core Insights - Kayne Anderson Energy Infrastructure Fund, Inc. reported a net asset value of $2.2 billion and a net asset value per share of $13.13 as of October 31, 2025 [2][3] - The company's asset coverage ratio for senior securities representing indebtedness was 663%, while the total leverage asset coverage ratio was 486% [2] Financial Summary - Total assets amounted to $3,088.9 million, with investments constituting $3,074.3 million and cash and cash equivalents at $2.2 million [3] - Total liabilities were reported at $296.6 million, which includes a credit facility of $22.0 million and notes of $400.0 million [3] Investment Composition - The company had 169,126,038 common shares outstanding as of October 31, 2025 [5] - Long-term investments were primarily in Midstream Energy Companies (95%), with smaller allocations in Power Infrastructure (3%) and Other (2%) [5] - The ten largest holdings included major companies such as The Williams Companies, Inc. ($325.8 million, 10.6%) and Enterprise Products Partners L.P. ($313.3 million, 10.2%) [5]

Reference is made to the private placement (the "Private Placement") and the retail offering through PrimaryBid (the "PrimaryBid Offering") announced by Zelluna ASA on 3 November 2025. Please see the attached PDMR-forms related to (i) allocation of shares in the Private Placement; and (ii) share lending to facilitate settlement of tranche 1 of the Private Placement and the PrimaryBid Offering. Attachment 20251104 - PDMR attachment ...

SPARTANBURG, S.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Denny’s Corporation (the "Company") (NASDAQ: DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's") today reported results for its third quarter ended September 24, 2025 and provided a business update on the Company’s operations. Kelli Valade, Chief Executive Officer, stated, "Our third quarter progress on strategic initiatives demonstrates our ability to remain agile and focused on what is within our control amid a choppy indust ...

Core Insights - Zelluna ASA has successfully raised NOK 58 million to advance its TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials for treating solid cancers [1][2][4] - The financing was strongly supported by existing shareholders and management, indicating confidence in the potential of Zelluna's TCR-NK platform [3][6] - The company aims to deliver a new generation of allogeneic "off-the-shelf" cell therapies, combining T-cell receptors with natural killer cells to enhance treatment efficacy [4][5] Financial Details - The private placement raised NOK 55 million through the allocation of 5,500,000 shares at NOK 10 per share, with an additional NOK 3.16 million raised from the PrimaryBid Offering [8][9] - The net proceeds will be utilized to initiate the Phase I clinical trial, develop the pipeline, and for general corporate purposes [9] Shareholder Engagement - The financing reflects strong investor confidence, with participation from both existing and new investors, showcasing a commitment to Zelluna's vision and scientific approach [5][6] - A subsequent repair offering of up to 800,000 new shares is planned to mitigate dilution effects for existing shareholders not participating in the private placement [18] Clinical Development - The company is positioned to initiate its first clinical study with the world's first MAGE-A4-targeting TCR-NK therapy, which could significantly impact treatment for solid tumors [4][5] - The successful financing marks a pivotal milestone in Zelluna's journey from innovation to clinical validation, with a focus on scalable "off-the-shelf" cell therapies [4][6]

SPARTANBURG, S.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Denny’s Corporation (the "Company") (NASDAQ: DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's") today announced that it will no longer hold its third quarter earnings conference call originally scheduled for 4:30 p.m. Eastern Time today in light of the announced transaction with TriArtisan Capital Advisors LLC, Treville Capital Group and Yadav Enterprises, Inc. Denny’s will release third quarter financial results after the st ...

Denny’s Stockholders to Receive $6.25 Per Share in Cash, Delivering Significant, Near-Term and Certain Cash Value Purchase Price Represents Premium of 52.1% to Closing Price on Monday, November 3 and 36.8% Premium to 90-Day VWAP SPARTANBURG, S.C. and NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Denny’s Corporation (the “Company” or “Denny’s”) (NASDAQ: DENN), owner and operator of Denny’s Inc. and Keke’s Inc., today announced that it has entered into a definitive agreement to be acquired by a group consisting ...

LISLE, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE: CTS) announced today that the company will participate in the 17th Annual Southwest IDEAS Conference on November 20, 2025, at The Westin Las Colinas in Dallas, TX. CTS’s presentation is scheduled to begin at 4:00 PM Central Time. You may access a live webcast of the event using this link or from the Investors section of the CTS Corporation website at www.ctscorp.com. The webcast will also be available for replay on the conference website ...

DUNMORE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Daniel J. Santaniello, President and CEO of Fidelity Bank, is pleased to announce that Charles Hangen has joined Fidelity Bank as SVP, Chief Risk Officer. Hangen will be responsible for safeguarding the Bank’s strategic integrity, this role leads to the identification and mitigation of critical competitive, regulatory, and technological risks. He will be focused on advancing the enterprise risk management framework and ensuring robust policies and procedures t ...